Completed PHASE4 INTERVENTIONAL 3-arm NCT04894227

Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults

A Double-blind, Randomized Clinical Trial to Evaluate the Lot-to-lot Consistency, Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac） in Health Adults Aged 26-45 Years

Sponsor: Sinovac Research and Development Co., Ltd.

Conditions COVID-19

Interventions Inactivated SARS-CoV-2 Vaccine (Vero cell）

Updated 5 times since 2021 Last updated: Apr 12, 2022 Started: May 11, 2021 Primary completion: May 11, 2021 Completion: Nov 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates COVID-19 and is currently completed. Sinovac Research and Development Co., Ltd. leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
May 2022 — Jul 2024 [monthly]

Completed PHASE4

Status: Active Not Recruiting → Completed
Sep 2021 — May 2022 [monthly]

Active Not Recruiting PHASE4

Status: Not Yet Recruiting → Active Not Recruiting
Jun 2021 — Sep 2021 [monthly]

Not Yet Recruiting PHASE4

First recorded

May 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sinovac Research and Development Co., Ltd.

Data source: Sinovac Biotech Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Huai'an, China